Cleerly, Inc., a digital healthcare company focused on AI-driven heart disease diagnosis, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online in the European Heart Journal Cardiovascular Imaging.
The RESILIENT-Extend trial showed benefit for thrombectomy in the 8- to 24-hour window without the need for costly imaging equipment, albeit with some caveats.